Skip to main content
contact
rss feedemail usour facebook page pintrest youtubeinstagram

 

SYMPTOMS:

Symptoms are usually the #1 indicator that you have been exposed to toxic mold in your environment. The first step is to identify your symptoms. Most victims will exhibit one, ten or up to twenty or more of these symptoms on a daily basis.  Scientific research is "overwhelming" if one were to spend the time to find it.  We have spent countless hours finding scientific and medical research to support symptoms and illnesses suspected as being caused by exposure to toxic molds. 

As you browse the extensive list below you will notice that the effects of mold exposure can be vast.  However, there are some "very common" symptoms that are the most common.  We have highlighted the

MOST COMMON SYMPTOMS in ORANGE

  • Balance & Coordination Dysfunction
  • Fatigue
  • Food Allergies
  • Weakness
  • Aches
  • Muscle Cramps
  • Unusual Pain
  • Ice Pick Pain
  • Headaches
  • Light Sensitivity
  • Red Eyes
  • Blurred Vision
  • Tearing
  • Sinus Problems
  • Cough
  • Shortness of Breath
  • Abdominal Pain
  • Diarrhea
  • Joint Pain
  • Morning Stiffness
  • Memory Issues
  • Focus/Concentration Issues
  • Word Recollection Issues
  • Decreased Learning of New Knowledge
  • Confusion
  • Disorientation
  • Skin Sensitivity
  • Mood Swings
  • Appetite Swings
  • Sweats (especially night sweats)
  • Temperature Regulation or Dysregulation Problems
  • Excessive Thirst
  • Increased Urination
  • Static Shocks
  • Numbness
  • Tingling
  • Vertigo
  • Vitamin Deficiencies
  • Metallic Taste
  • Tremors 


Here is a good scientific study that is archived in the US National Library of Medicine: "Indoor Mold, Toxigenic Fungi and Stachybotrys Chartarum: An Infectious disease perspective https://www.ncbi.nlm.nih.gov/pmc/articles/PMC145304/


WHAT IS MYCOTOXICOSIS?
Mycotoxicoses, like all toxicological syndromes, can be categorized as acute or chronic. Acute toxicity generally has a rapid onset and an obvious toxic response, while chronic toxicity is characterized by low-dose exposure over a long time period, resulting in cancers and other generally irreversible effects (James, 2005).

Common Symptoms Reported & Documented as a result of cellular and DNA death caused by mycotoxin toxicity in the body

Important information about Symptoms
Because many of these symptoms can be connected to many other diseases or toxicities one MUST be sure they are dealing with toxic mold.  Currently the only way to prove that a person's symptoms are related to toxic mold spores that put off toxins called "mycotoxins" is to be tested for the presence of "mycotoxins" in the body.  This can be done through labs in the United States at Great Plains Lab HERE: or also at RealTime Lab: HERE

Here is a VERY detailed list of symptoms. We have listed them A-Z.

ALLERGIES & NEW ONSET SENSITIVITIES

AUTO IMMUNE DIAGNOSIS

MOLD, MYCOTOXINS & AUTOIMMUNITY; IS THERE A LINK? (Read)

  • MS (Multiple Sclerosis)
    http://www.ncbi.nlm.nih.gov/pubmed/20214953 - Direct connection between the cause of MS and Fungal Mycotoxins
  • Lupus
    • Invasive aspergillosis associated with systemic lupus erythematosus
    • https://journalofethics.ama-assn.org/article/what-primary-physicians-should-know-about-environmental-causes-illness/2009-06

BLADDER

BLOOD

BONES

BRAIN & NERVOUS SYSTEM - (also see "mental" below)

BREAST FEEDING (studies on breast feeding and mold exposure)

CANCERS

Fungi can be detected in 35 cancer types
https://www.news-medical.net/news/20221122/Fungi-detected-in-35-cancer-types-often-intracellular.aspx

CARDIOVASCULAR & CIRCULATORY SYSTEM

High Cholesterol - https://pubs.acs.org/doi/10.1021/acs.chemrestox.9b00378

Affects of mycotoxins on the cardiovascular system - https://www.researchgate.net/publication/305482747_Mycotoxins_that_Affect_the_Human_Cardiovascular_System

 

DEFICIENCIES - (Secondary symptoms as a result of fungi entering the small intestine)

EARS

EYES

The three most common conditions caused by mold are “pink eye,” chronic dry eye, and fungal keratitis.

  • Blurred Vision
  • Eye Twitching
  • Red eyes
  • Eye inflammation (Glaucoma)
  • Sore, tired eyes
  • Dry eyes
  • Itchy/Watery eyes
  • Yellowing of the eyes (as the result of toxic liver from mycotoxin)
  • Droopy eye - One eye droops more than the other or won't open all the way (all of a sudden)
  • Floaters in eyes (Usually black colored indicates possible mold exposure)
  • Intolerance of bright lights
  • Vision changes: (Sudden extreme or sudden mild vision changes needing an eye exam)
  • Vision: Seeing halos around everything (White borders)
  • Vision: Feels like everything is flashing
  • Eye infections bacterial (Conjunctivitus)
  • Eye infections fungal: (Keratitus)

FATIGUE

GROWTH

GUT

HAIR & SCALP

HEART

  • POTS (Postural Tachycardia Syndrome: Rapid heart rate when doing normal activities ie: sitting, standing or laying down (absent of a known heart condition) 
    http://www.ipej.org/0602/raj.htm
  • Facial flushing
  • Fainting feeling (without actually fainting)
  • Fight or Flight heart beating fast feeling (losing control/feeling like you are going to die)
  • Heart Palpitations (no known reason...just all of a sudden feel your heart beat funny then go back to normal)
    See vitamin D and Calcium deficiency related to mycotoxins http://www.ncbi.nlm.nih.gov/pubmed/2275121
    then read "Heart Palps" related to Vitamin D deficiencies http://knowledgeofhealth.com/is-this-cause-heart-palpitations/
  • High Blood Pressure - Antidiuretic hormone – This hormone is responsible for the regulation and balance of water in your body, your blood pressure, and concentration of urine being made in your kidneys. Reduced levels of ADH for a mold patient means that you suffer from dehydration, increased thirst, and frequent urination.

HORMONES

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983244/
https://www.frontiersin.org/articles/10.3389/fcimb.2018.00060/full
http://www.diabetesandenvironment.org/home/contam/microbial-toxins

IMMUNE SYSTEM

KIDNEYS

LIVER

LUNGS

MENTAL

MUSCLES

MOUTH & TROAT

NEUROLOGICAL

PAIN & INFLAMMATION

PANCREAS

REPRODUCTIVE

Infertility - https://www.jri.ir/article/113

SKIN, NAILS, HAIR

SINUSES

SLEEP

  • Sleep disturbance (Being awaken several times during sleep for no other known medical reason)
  • Insomnia
  • Night Terrors

THROAT & NECK

  • Scratchy throat that won't go away
  • Sore throat that "will not go away" or "keeps coming back daily" (especially after sleep/after waking up)
  • Throat burning

WOMENS HEALTH

YEAST INFECTION

WHOLE BODY

INFLAMMATION 

  • Trichothecene causes inflammatory response https://www.jimmunol.org/content/182/10/6418
  • Mold and Mycotoxins elicit cytokine responses https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444319/
  • Inflammation caused by mold and mycotoxins in water-damaged buildings https://www.hindawi.com/journals/tswj/2013/767482/y

WEAKNESS

 

 

 

 

 

Commonly Diagnosed Conditions, Disorders & Diseases that
"CAN BE" caused by Toxic Mold Exposure via Mycotoxin

Autism Alzheimers Anxiety Attacks/Panic Attacks/GAD Cancers Celiac Chronic Fatigue Syndrome Crohn's Disease Cystic Fibrosis Endometriosis Fibromyalgia Gallstones Gout Chronic Granulomatous Disease (CGD) Guillain-Barre' Syndrome HyperAldosteronism/Conn's Disease Kidney Disease or Failure Lupus MS (Multiple Sclerosis) Myasthena Gravis Narcolepsy Parkinsons Polymyositis or Dermatomyositis Psoriasis Rheumatoid Arthritis Scleroderma Sjogren's Syndrome Thyroiditis (Hashimoto's Diseaseor Grave's Disease) Type I Diabetes Ulcerative Colitis

Is mold making you sick?  Put the effects of Toxic Mold behind you!!

Do you think you might have mold in your home, place of business or school? Are you or someone you love suffering from an unknown illness that doctors can't diagnose?  Is mold making you sick? Go to our Step by Step and start Surviving Toxic Mold.

Symptoms of Trichothecene exposure

NAME, SYMPTOM (description) (references)

  1. Abdominal pain (Haig, 1982; Schultz, 1982; Watson, Mirocha, and Hayes, 1984; Stahl et al., 1985; Crossland and Townsend, 1984).
  2. Acute myocarditis (inflammation of the heart muscle) (Stahl, Green, and Farnum, 1985).
  3. Acute renal tubular necrosis (damage to the renal tubule cells) (Stahl, Green, and Farnum, 1985).
  4. Adrenal cortical necrosis (death of the outer level of the adrenal gland) (Thurman et al., 1986).
  5. Affects hydroxyindoleacetic acid levels (Wang, Wilson, and Fitzpatrick, 1992).
  6. Affects seratonin levels (Wang, Wilson, and Fitzpatrick, 1992).
  7. Alimentary toxic aleukia (Ueno et al., 1984). Mayer 1953a, 1953 b; Lutsky et al., 1978).
  8. Alopecia (hair loss) (Croft et al.,1986; Jarvis, 1985)
  9. Alterations in hemostasis (clotting) (Cosgriff et al., 1986).
  10. Anariax (anaphylaxia, anoxic?) coma (allergic or lack of oxygen) (Stahl, Green, and Farnum, 1985).
  11. Anorexia (Creasia et al., 1987; Bonomi et al., 1995; Wannemacher et al., 1993; Schiefer and Hancock, 1984)
  12. Anxiety (Yap et al., 1979; Thigpen et al., 1981; Bukowski et al., 1982).
  13. Aphonia (loss of hearing) (Rukmini, Prasad, and Rao, 1980; Lutsky et al., 1978; Bunner, 1983; Bunner et al. 1985).
  14. Arrhythmias (abnormal heart rhythm) (Ueno et al., 1984; Stahl et al., 1985),
  15. Bleeding gums (Watson, Mirocha, and Hayes, 1984).
  16. Bleeding tendency (Creasia et al., 1987; Bonomi et al., 1995; Wannemacher et al., 1993; Schiefer and Hancock, 1984)
  17. Blisters (Haig, 1982; Schultz, 1982; Crossland and Townsend, 1984).
  18. Blurred vision (Bunner, 1983).
  19. Bone marrow aplasia (bone marrow stops producing blood cells) (Mayer 1953a, 1953b)
  20. Bone marrow injury (Mayer 1953a, 1953b; Ueno et al., 1984).
  21. Breath holding (Otto et al., 1989)
  22. Breathlessness (Kemppainen et al., 1986b; Hendy and Cole, 1993; Jarvis, 1985).
  23. Burning erythema (red skin with a burning sensation) (Belt et al., 1979; Murphy et al., 1978; Yap, et al., 1979; Diggs et al., 1978; Bukowski et al., 1982; Thigpen et al., 1981; Crossland and Townsend, 1984).
  24. Burning of the skin (Watson, Mirocha, and Hayes, 1984).
  25. Burning stomatitis (burning sensation of the mouth) (Schiefer and Hancock, 1984; Murphy et al., 1978; Bukowski et al., 1982; Diggs et al., 1978; Belt et al., 1979; Yap et al., 1979; Thigpen et al., 1981; Goodwin et al., 1981).
  26. Cardiac injury (heart injury) (Bunner, 1983).
  27. Cerebral hemorrhage (bleeding in the brain) (Coppock et al., 1985)
  28. Chest pain (Watson, Mirocha, and Hayes, 1984).
  29. Chills (Belt et al., 1979; Murphy et al., 1978; Yap, et al., 1979; Diggs et al., 1978; Bukowski et al., 1982; Thigpen et al., 1981; Crossland and Townsend, 1984).
  30. CNS dysfunction (Wannemacher and Wiener, 1997).
  31. CNS toxicity ( Watson, Mirocha, and Hayes, 1984; Bunner et al., 1985; and Wannemacher and Wiener, 1997).
  32. Cold and flu symptoms (Croft et al.,1986; Jarvis, 1985)
  33. Confusion (Belt et al., 1979; Murphy et al., 1978; Yap, et al., 1979; Diggs et al., 1978; Bukowski et al., 1982; Thigpen et al., 1981; Crossland and Townsend, 1984).
  34. Conjunctivitis (inflammation of the eye) (Bunner, 1983).
  35. Corneal changes (changes in the cornea of the eye) (Bunner, 1983).
  36. Corneal thinning (Bunner, 1983).
  37. Cough (Croft et al.,1986; Jarvis, 1985)
  38. Cramps (Bunner, 1983).
  39. Cytolysis (rupturing of cell membranes) (Lee et al., 1984; Rukmini, Prasad, and Rao, 1980).
  40. Death (Rukmini, Prasad, and Rao, 1980; Lutsky et al., 1978; Bunner, 1983; Bunner et al. 1985).
  41. Decreased attention (Otto et al., 1989)
  42. Decreased coagulation factors (blood does not clot properly) (Yarom et al., 1984).
  43. Decreased learning (Umeuchi et al., 1996).
  44. Decreased sperm production
  45. Decreased vision (Watson, Mirocha, and Hayes, 1984).
  46. Depressed immunoglobulin levels (immune system not functioning) (Jagadeesan et al., 1982; Schiefer, 1984; Ueno et al., 1984).
  47. Depression (Thigpen et al., 1981; Yap et al., 1979; Croft et al., 1986; Watson, Mirocha, and Hayes, 1984; Crossland and Townsend, 1984)
  48. Dermatitis (inflammation or irritation of the skin) (Kemppainen et al., 1986b; Hendy and Cole, 1993; Jarvis, 1985).
  49. Diarrhea (Ueno et al., 1984).
  50. Diffuse hepatitis (widespread inflammation of the liver) (Stahl, Green, and Farnum, 1985).
  51. Dilation of surface blood vessels (causes reddening of the skin) (Otto et al., 1989)
  52. Diminished reflex time (Otto et al., 1989)
  53. Disorientation (Otto et al., 1989)
  54. Dizziness (Haig, 1982; Schultz, 1982; Crossland and Townsend, 1984).
  55. Drowsiness (Yap et al., 1979; Thigpen et al., 1981; Bukowski et al., 1982).
  56. Dyspnea (shortness of breath) (Creasia et al., 1987; Bonomi et al., 1995; Wannemacher et al., 1993; Schiefer and Hancock, 1984)
  57. ECG prolonged P-R intervals (Ueno et al., 1984; Stahl et al., 1985),
  58. ECG prolonged QRS and QRT intervals (Ueno et al., 1984; Stahl et al., 1985),
  59. Edema (swelling due to extra fluid in the body) (Rukmini, Prasad, and Rao, 1980; Lutsky et al., 1978; Bunner, 1983; Bunner et al. 1985).
  60. Elevated serum creatine-kinase (too much creatine-kinase in the blood) (Bunner, 1983).
  61. Epithelial necrosis (death of epithelial cells i.e. skin) (Wannemacher and Wiener, 1997).
  62. Eye injury (Watson, Mirocha, and Hayes, 1984; Bunner et al., 1985; and Wannemacher and Wiener, 1997).
  63. Eye pain (Watson, Mirocha, and Hayes, 1984).
  64. Eyelid edema (swelling of the eyelid) (Bunner, 1983).
  65. Fatigue (Haig, 1982; Schultz, 1982; Crossland and Townsend, 1984).
  66. Fetal abnormalities (Haig, 1982; Schultz, 1982; Watson, Mirocha, and Hayes, 1984; Stahl et al., 1985; Crossland and Townsend, 1984).
  67. Fever (Belt et al., 1979; Murphy et al., 1978; Yap, et al., 1979; Diggs et al., 1978; Bukowski et al., 1982; Thigpen et al., 1981; Crossland and Townsend, 1984).
  68. Fibrinous exudate (fibrin escaping from the blood vessels) (Goodwin et al., 1981).
  69. Gastroenteritis (acute inflammation of the lining of the stomach and intestines) (Wannemacher and Wiener, 1997).
  70. Gastrointestinal toxicity (Watson, Mirocha, and Hayes, 1984; Bunner et al., 1985; and Wannemacher and Wiener, 1997).
  71. Gastrointestinal tract necrosis (toxicity of the stomach and intestines) (Coppock et al., 1985)
  72. Hallucinations (false perception of sight, hearing, smell, taste, or touch) (Belt et al., 1979; Murphy et al., 1978; Yap, et al., 1979; Diggs et al., 1978; Bukowski et al., 1982; Thigpen et al., 1981; Crossland and Townsend, 1984).
  73. Headaches (Croft et al.,1986; Jarvis, 1985)
  74. Hematemesis (throwing up blood) (Haig, 1982; Schultz, 1982; Crossland and Townsend, 1984).
  75. Hematological toxicity (blood toxicity) (Watson, Mirocha, and Hayes, 1984; Bunner et al., 1985; and Wannemacher and Wiener, 1997).
  76. Hemorrhagic bullae (large blisters that pop easily) (Wannemacher and Wiener, 1997).
  77. Hemorrhagic diathesis (bleeding tendency) (Ueno et al., 1984).
  78. Hemorrhagic foci (group of cells prone to hemorrhaging) (Ueno et al., 1984; Stahl et al., 1985),
  79. Hemoptysis (spitting up blood) (Stahl, Green, and Farnum, 1985).
  80. Hyperglycemia (too much sugar in the blood) (Coppock et al., 1985)
  81. Hyperpigmentation (unusual skin darkening in a specific area) (Wannemacher and Wiener, 1997).
  82. Hypotension (low blood pressure) (Haig, 1982; Schultz, 1982; Crossland and Townsend, 1984).
  83. Hypothermia (low body temperature) (Wannemacher and Wiener, 1997).
  84. Hypoxia (low oxygen in the arteries) (Rukmini, Prasad, and Rao, 1980; Lutsky et al., 1978; Bunner, 1983; Bunner et al. 1985).
  85. Immunosupression (immune system dysfunction) (Ueno, 1983; Yarom et al., 1984; Jagadeesan et al., 1982).
  86. Impairment of ribosome function (NAS, 1983; Coulombe, 1993; Tutelyan and Kravchenko, 1981)
  87. Impotence (inability to achieve erection or ejaculation) (Haig, 1982; Schultz, 1982; Watson, Mirocha, and Hayes, 1984; Stahl et al., 1985; Crossland and Townsend, 1984).
  88. Increased partial thromboplastin times blood test (Yarom et al., 1984).
  89. Increased prothrombin times (increased clotting time) (Yarom et al., 1984).
  90. Increased vascular fragility (blood vessels are more fragile) (Smith and Moss, 1985).
  91. Induction of reparable single strand DNA breaks
  92. Inhibition of mitochondrial protein synthesis (Pace et al., 1985)
  93. Inhibition of platelet aggregation (Yarom et al., 1984).
  94. Inhibition of protein synthesis (Ueno, 1983; Ueno et al., 1984; Tutelyan and Kravchenko, 1981)
  95. Inhibition of thiol enzymes (Tutelyan and Kravchenko, 1981; Ueno et al., 1984)
  96. Inhibition on DNA synthesis (Thompson and Wannemacher, 1984)
  97. Interstitial myocardial hemorrhage (hemmhorage in between the myocardium) (Stahl, Green, and Farnum, 1985).
  98. Itching (Watson, Mirocha, and Hayes, 1984).
  99. Jaundice (yellowing of the skin and eyes from excess bilirubin in the blood) (Stahl, Green, and Farnum, 1985).
  100. Joint pain (Haig, 1982; Schultz, 1982; Crossland and Townsend, 1984).
  101. Leukopenia (shortage of white blood cells) (Ueno et al., 1984).
  102. Lymphatic changes (changes in the lymph system) (Schiefer, 1984; Wannemacher et al., 1983).
  103. Malaise (vague feeling of discomfort, or that something is not right) (Thigpen et al., 1981; Yap et al., 1979; Croft et al., 1986; Watson, Mirocha, and Hayes, 1984; Crossland and Townsend, 1984)
  104. Melena (blood in the stool) (Wannemacher and Wiener, 1997).
  105. Memory loss (Belt et al., 1979; Murphy et al., 1978; Yap, et al., 1979; Diggs et al., 1978; Bukowski et al., 1982; Thigpen et al., 1981; Crossland and Townsend, 1984).
  106. Memory problems (Haig, 1982; Schultz, 1982; Crossland and Townsend, 1984).
  107. Meningeal bleeding (bleeding in the meninges of the brain) (Ueno et al., 1984).
  108. Micronodular cirrhosis (complication of liver disease) (Stahl, Green, and Farnum, 1985).
  109. Muscle injury (Bunner, 1983).
  110. Myelosuppression (suppression of bone marrow activity) (Wannemacher and Wiener, 1997).
  111. Nasal itching (Rukmini, Prasad, and Rao, 1980; Lutsky et al., 1978; Bunner, 1983; Bunner et al. 1985).
  112. Nasal stuffiness (Bell, et al., 1993a; Bell et al., 1993b)
  113. Nausea (Ueno et al., 1984).
  114. Neuropsychiatric manifestations (neurobiological brain disorders) (Forgacs, 1972)
  115. Neurotoxic (brain and nerve toxin) (Thigpen et al., 1981; Yap et al., 1979; Croft et al., 1986; Watson, Mirocha, and Hayes, 1984; Crossland and Townsend, 1984)
  116. Numbness (Schiefer and Hancock, 1984; Murphy et al., 1978; Bukowski et al., 1982; Diggs et al., 1978; Belt et al., 1979; Yap et al., 1979; Thigpen et al., 1981; Goodwin et al., 1981).
  117. Oral mucosal necrosis (death of tissue in the mouth) (Mayer 1953a, 1953b)
  118. Orthostatic hypotension (low blood pressure when lying down) (Yap et al., 1979; Thigpen et al., 1981; Murphy et al., 1978; Bukowski et al., 1982).
  119. Pain (Wannemacher and Wiener, 1997).
  120. Pancreatic damage (Coppock et al., 1985)
  121. Paresthesia (abnormal sensations, such as numbness, tingling, or burning ) (Otto et al., 1989)
  122. Petechial rashes (rash caused by bleeding under the skin) (Ueno et al., 1984).
  123. Prolonged rashes (Schultz, 1982)
  124. Pulmonary collapse (lung collapse) (Rukmini, Prasad, and Rao, 1980; Lutsky et al., 1978; Bunner, 1983; Bunner et al. 1985).
  125. Pulmonary consolidation (Rukmini, Prasad, and Rao, 1980; Lutsky et al., 1978; Bunner, 1983; Bunner et al. 1985).
  126. Pulmonary edema (swelling of the lung) (Stahl, Green, and Farnum, 1985).
  127. Pulmonary fibrosis (Scarring throughout the lungs) (Goodwin et al., 1981).
  128. Pulmonary hemorrhage (bleeding in the lungs) (Rukmini, Prasad, and Rao, 1980; Lutsky et al., 1978; Bunner, 1983; Bunner et al. 1985).
  129. Rashes (Haig, 1982; Schultz, 1982; Crossland and Townsend, 1984).
  130. Red eyes (Watson, Mirocha, and Hayes, 1984).
  131. Reduced concentration (Haig, 1982; Schultz, 1982; Watson, Mirocha, and Hayes, 1984; Stahl et al., 1985; Crossland and Townsend, 1984).
  132. Regional norepinephrine increases (Wang, Wilson, and Fitzpatrick, 1992).
  133. Reoccurant infections (Creasia et al., 1987; Bonomi et al., 1995; Wannemacher et al., 1993; Schiefer and Hancock, 1984)
  134. Respiratory distress (Haig, 1982; Schultz, 1982; Crossland and Townsend, 1984).
  135. Respiratory illness (Croft et al., 1986; Jarvis, 1985)
  136. Respiratory toxicity (Watson, Mirocha, and Hayes, 1984; Bunner et al., 1985; and Wannemacher and Wiener, 1997).
  137. Rhinorrhea (runny nose) (Rukmini, Prasad, and Rao, 1980; Lutsky et al., 1978; Bunner, 1983; Bunner et al. 1985).
  138. Scleral inflammation (inflammation of the sclera in the eye) (Bunner, 1983).
  139. Seizures (Haig, 1982; Schultz, 1982; Crossland and Townsend, 1984).
  140. Sepsis (infection of the blood stream) (Ueno et al., 1984).
  141. Shock (Rukmini, Prasad, and Rao, 1980; Lutsky et al., 1978; Bunner, 1983; Bunner et al. 1985).
  142. Skin crawling (Otto et al., 1989)
  143. Skin injury (Watson, Mirocha, and Hayes, 1984; Bunner et al., 1985; and Wannemacher and Wiener, 1997).
  144. Sloughing of gastric epithelium (shedding of the epithelium in the stomach) (Lee et al., 1984; Rukmini, Prasad, and Rao, 1980).
  145. Sloughing of gastric villus tips (shedding of the villus tips in the stomach) (Lee et al., 1984; Rukmini, Prasad, and Rao, 1980).
  146. Somnolence (feeling drowsy) (Belt et al., 1979; Murphy et al., 1978; Yap, et al., 1979; Diggs et al., 1978; Bukowski et al., 1982; Thigpen et al., 1981; Crossland and Townsend, 1984).
  147. Sore throats (Croft et al.,1986; Jarvis, 1985)
  148. Spontaneous abortion (Haig, 1982; Schultz, 1982; Watson, Mirocha, and Hayes, 1984; Stahl et al., 1985; Crossland and Townsend, 1984).
  149. Suppressed cell-mediated immunity (Jagadeesan et al., 1982; Schiefer, 1984; Ueno et al., 1984).
  150. Tachycardia (fast heart beat) (Watson, Mirocha, and Hayes, 1984).
  151. Tearing (Bunner, 1983).
  152. Thrombocytopenia (decreased number of platelets in the blood) (Creasia et al., 1987; Bonomi et al., 1995; Wannemacher et al., 1993; Schiefer and Hancock, 1984)
  153. Thymus changes (Schiefer, 1984; Wannemacher et al., 1983).
  154. Tingling (Wannemacher and Wiener, 1997).
  155. Trembling (Watson, Mirocha, and Hayes, 1984).
  156. Vasodilatation (widening of the blood vessels) (Ueno et al., 1984; Stahl et al., 1985),
  157. Vomiting (Ueno et al., 1984).
  158. Weakness (Creasia et al., 1987; Bonomi et al., 1995; Wannemacher et al., 1993; Schiefer and Hancock, 1984)
  159. Weight loss (Creasia et al., 1987; Bonomi et al., 1995; Wannemacher et al., 1993; Schiefer and Hancock, 1984)
  160. Wheezing (Kemppainen et al., 1986b; Hendy and Cole, 1993; Jarvis, 1985).

Bibliography

Belt RJ, Haas CD, Joseph U, Goodwin W, Moore D, and Hoogstraten B, "Phase I Study of Anguidine Administered Weekly," Cancer Treat Rep, 63, 1979, pp. 1993-1995.

Bonomi A, Quarantelli A, Zambin EM, et al., "Effects of Aflatoxin B1 Contaminated Rations on Productive and Reproductive Efficiency in Swine (Experimental Contribution)," Rivista Di Scienza Dell'Alimentazione, 24, 1995, pp. 361-384.

Buck WB, Beasley VR, and Swanson SP, Toxicologic and Analytical Studies with T-2 and Related Trichothecene Mycotoxins, Ft. Detrick, Md.: U.S. Army Medical Research and Development Command, DTIC ADA172207, 1983.

Bukowski R, Vaughn C, Bottomley R, and Chen T, "Phase II Study of Anguidine in Gastrointestinal Malignancies: A Southwest Oncology Group Study," Cancer Treat Rep, 66, 1982, pp. 381-383.

Bunner D, Trichothecene Mycotoxins Intoxications: Signs, Symptoms, Pathophysiology, and Management (Based On Initial Laboratory Animal Studies and Review of Phase I Trails as Anticancer Agents in Man, Ft. Detrick, Md.: U.S. Army Medical Research Institute of Infectious Diseases, 1983.

Bunner D, Wannemacher R, Neufeld H, Hessler C, Parker G, Cosgriff T, and Dinterman R, "Pathophysiology of Acute T-2 Intoxication in the Cynomolgus Monkey and Comparison to the Rat as Model," Ft. Detrick, Md.: U.S. Army Medical Research Institute of Infectious Diseases, DTIC ADA135983, 1983.

Bunner DL, Neufeld HA, Brennecke LH, Campbell YG, Dinterman RE, and Pelosi JG, Clinical and Hematologic Effects of T-2 Toxin in Rats, Ft. Detrick, Md.: U.S. Army Medical Research Institute of Infectious Diseases, DTIC ADA158874, 1985.

Chan PKC, and Gentry PA, "LD50 Values and Serum Biochemical Changes induced by T-2 Toxin Rats and Rabbits," Toxicol Appl Pharmacol, 73, 1984, pp. 402-410.

Coppock RW, Gelberg HB, Hoffmann I, and Buck WB, "The Acute Toxicopathy of Intravenous Diacetoxyscirpenol (Anguidine) Administration in Swine," Fund Appl Toxicol, 5, 1985, pp. 1034-1049.

Cosgriff TM, Bunner DL, Wannemacher RW, Jr., Hodgson LA, and Dinterman RE, "The Hemostatic Derangement Produced by T-2 Toxin in Cynomolgus Monkeys," Toxicol Appl Pharmacol, 82, 1986, pp. 532-539.

Coulombe RA, Jr., "Symposium: Biological Action of Mycotoxins," J Dairy Sci, 76, 1993, pp. 880-891.

Coulombe RAJ, Huie JM, Ball RW, Sharma RP, and Wilson DW, "Pharmacokinetics of Intratracheally Administered Aflatoxin B1," Toxicol Appl Pharmacol, 109, 1991, pp. 196-206.

Creasia DA, Thurman JD, Jones LJI, et al., "Acute Inhalation Toxicity of T-2 Mycotoxin in Mice," Fund Appl Toxicol, 8, 1987, pp. 230-235.

Croft WA, Jarvis BB, and Yatawara CS, "Airborne Outbreak of Trichothecene Toxicosis," Atmos Environ, 20, 1986, pp. 549-552.

Crossland A, and Townsend A, "Observations, Impressions, Pitfalls and Recommendations from Field CBW Research Among Refugees in Southeast Asia," in First World Congress: New Compounds in Biological Warfare: Toxicological Evaluation, Proceedings, Ghent, Belgium: State University of Ghent and National Science Foundation, 1984.

Di Paolo N, Guarnieri A, Gariso G, Sacchi G, Mangiarotti AM, and Di Paolo M, "Inhaled Mycotoxins Lead to Acute Renal Failure," Nephrol Dial Transplan, 9, 1994, pp. 116-120.

Diggs CH, Scoltock MJ, and Wiernik PH, "Phase II Evaluation of Anguidine (NSC-141537) for Adenocarcinoma of the Colon or Rectum," Cancer Clin Trials, Winter 1978, pp. 297-299.

Dugyala RR, Kim YW, et al., "Effects of Aflatoxin B1 and T-2 Toxin on the Granulocyte-Macrophage Progenitor Cells in Mouse Bone Marrow Cultures," Immunopharmacol, 27, 1994, pp. 57-65.

Fontelo PA, Beheler J, Bunner DL, and Chu FS, "Detection of T-2 Toxin by an Improved Radioimmunoassay," Appl Environ Microbiol, 45, 1983, pp. 640-643.

Forgacs J, "Stachybotrytoxicosis," in Kadis et al., eds., Microbial Toxins VIII, New York: Academic Press, 1972, pp. 294-298.

Fricke RF, "Decreased Toxicity of T-2 Mycotoxicosis in Mice Pre-Treated with Microsomal Enzyme Inducers," Abstract #1955, Fed Proc, 42, 1993, p. 626.

Goodwin W, Stephens R, McCracken JD, and Groppe C, "Therapy for Advanced Colorectal Cancer with a Combination of 5FU and Anguidine: A Southwest Oncology Group Study," Cancer Treat Rep, 65, 1981, p. 359.

Griffiths BB, Rea WJ, Johnson AR, and Ross GH, "Mitogenic Effects of Mycotoxins on T4 Lymphocytes," Microbios, 86, 1996, pp. 127-134.

Haig AM, Jr., Chemical Warfare in Southeast Asia and Afghanistan, Washington, D.C.: U.S. Department of State, 1982.

Hendry KM, and Cole EC, "A Review of Mycotoxins in Indoor Air," J Toxicol Environ Health, 38, 1993, pp. 183-198.

Huff WE, Harvey RB, Kubena LF, Rottinghause GE, "Toxic Synergism Between Aflatoxin and T-2 Toxin in Broiler Chickens," Poult Sci, 67 (10), October 1988, pp. 1418-1423.

Jagadeesan V, Rukmini C, Vijayaraghavan M, and Tulpule PG, "Immune Studies with T-2 Toxin Effect of Feeding and Withdrawal in Monkeys," Food Chem Toxicol, 20 (1), February 1982, pp. 83-87.

Jarvis BB, "Tricothecene Mycotoxins: Preparation, Analysis, and Chemical Reactivity," College Park, Md.: University of Maryland, 1985.

Johnsen H, Edden E, Lie O, Johnsen BA, and Fonnum F, "Metabolism of T-2 Toxin by Rat Liver Carboxytesterase," Biochem Pharmacol, 35, 1986, pp. 1469-1473.

Kemppainen BW, Riley RT, Pace JG, and Hoerr FJ, "Effects of Skin Storage Conditions and Concentration of Applied Dose on [3H]T-2 Toxin Penetration Through Excised Human and Monkey Skin," Fund Chem Toxic, 24, 1986, pp. 221-227.

Kemppainen BW, Riley RT, Pace JG, Hoerr FJ, and Joyave J, "Evaluation of Monkey Skin as a Model for in Vitro Percutaneous Penetration and Metabolism of [3H]T-2 Toxin in Human Skin," Fund Appl Toxicol, 7, 1986, pp. 367-375.

Lee SC, Beery JT, and Chu FS, "Immunoperoxidase Localization of T-2 Toxin," Appl Pharmacol, 72, 1984, pp. 228-235.

Lutsky I, Mor N, Yagen B, and Joffe AZ, "The role of T-2 Toxin in Experimental Alimentary Toxic Aleukia: A Toxicity Study in Cats," Toxic Appl Pharmacol, 43, 1978, pp. 111-124.

Mayer CF, "Endemic Panmyelotoxicosis in the Russian Grain Belt, Part One: The Clinical Aspects of Alimentary Toxic Aleukia (ATA): A Comprehensive Review," Mil Surg, 113, 1953a, pp. 173-189.

Mirocha CJ, Pawlosky RJ, and Chatterjee K, "Analytical Methodology, Detection of Trichothecenes from Southeast Asian Samples and Their Residue in Animal Tissue," First World Congress: New Compounds in Biological Warfare: Toxicological Evaluation, Proceedings, Ghent, Belgium: State University of Ghent and National Science Foundation, 1984.

Murphy WK, Burgess MA, Valdivieso M, Livingston RB, and Bodey GP, Freireich EJ, "Phase I Clinical Evaluation of Anguidine," Cancer Treat Rep, 62, 1978, pp. 1497-1502.

NAS-see National Academy of Sciences.

National Academy of Sciences, National Research Council, Committee on Toxicology, Possible Long-Term Health Effects of Short-Term Exposure to Chemical Agents, Vol. 1: Anticholinesterases and Anticholinergics, Washington, D.C.: National Academy Press, 1982.

National Academy of Sciences, Protection Against Trichothecene Mycotoxins, Washington, D.C.: National Academy Press, 1983.

Otto S, The Ocular Action of Dichlorethyl Sulfide (Mustard Gas) in Man, as Seen at Edgewood Arsenal, Edgewood, Maryland, DTIC AD495 508, 1946.

Pace JG, Watts MR, Burrows EP, et al., Fate and Distribution of 3H-Labeled T-2 Mycotoxin in Guinea Pigs, Toxicol Appl Pharmacol, 80, 1985, pp. 377-385.

Rukmini C, Prasad JS, and Rao K, "Effects of Feeding T-2 Toxin to Rats and Monkeys," Food Cosmet Toxicol, 18, 1980, pp. 267-269.

Schiefer HB, "Systemic Effects of Topical Application of Trichothecenes in Rodents," First World Congress: New Compounds in Biological Warfare: Toxicological Evaluation, Proceedings, Ghent, Belgium: State University of Ghent and National Science Foundation, 1984.

Schiefer HB, and Hancock DS, "Systemic Effects of Topical Application of T-2 Toxin in Mice," Toxicol Appl Pharmacol, 76, 1984, pp. 464-472.

Schnurr PP, Friedman MJ, and Green BL, "Post-Traumatic Stress Disorder Among World War II Mustard Gas Test Participants," Mil Med, 161, 1996, pp. 131-16O.

Schultz GP, Chemical Warfare in Southeast Asia and Afghanistan: An Update, Washington, D.C.: U.S. Department of State, 1982.

Seagrave S, Yellow Rain: A Journey Through the Terror of Chemical Warfare, New York: M. Evans and Company, Inc., 1981.

Segal R, Milo I, Joffe A, and Yogen B, "Tricothecene Induced Hemolysis," Toxicology and Applied Pharmacology, 70, 1983, p. 343.

Segal R, Milo I, Joffe A, and Yogen B, "Tricothecene Induced Hemolysis," Toxicology and Applied Pharmacology, 70, 1983, p. 343.

Smith KJ, Hurst CG, Moeller RB, Skelton HG, and Sidell FR, Sulfur "Mustard: Its Continuing Threat as a Chemical Warfare Agent, the Cutaneous Lesions Induced, Progress in Understanding Its Mechanism of Action, Its Long-Term Health Effects, and New Developments for Protection and Therapy," J Am Acad Derm, 32, 1995, pp. 765-766.

Smith TC, Gray GC, and Knoke JD, "Post-War Non-Federal Hospitalization Experience of U.S. Veterans of the Persian Gulf War," Conference on Federally Sponsored Gulf War Veterans' Illnesses Research, Conference Proceedings, June 17-19, 1998, p. 48.

Smith WJ, and Dunn MA, "Medical Defense Against Blistering Chemical Warfare Agents," Arch Dermatol, 127, 1991, pp. 1207-1213.

Smoragiewicz W, Cossette B, Boutard A, and Krzystyniak K, "Trichothecene Mycotoxins in the Dust of Ventilation Systems in Office Buildings," Int Arch Occup Environ Health, 65, 1993, pp. 113-117.

Solberg VB, Broski FH, Dinterman RE, and George DT, "Penetration of Tritiated T-2 Mycotoxin Through Abraded and Intact Skin and Methods to Decontaminate Tritiated T-2 Mycotoxin from Abrasions," Toxicol, 28, 1990, pp. 803-812.

Solberg VB, Broski FH, Dinterman RE, and George DT, "Penetration of Tritiated T-2 Mycotoxin Through Abraded and Intact Skin and Methods to Decontaminate Tritiated T-2 Mycotoxin from Abrasions," Toxicol, 28, 1990, pp. 803-812.

Stahl CJ, Green CC, and Farnum JB, "The Incident at Tuol Chrey: Pathologic and Toxicologic Examinations of a Casualty After Chemical Attack," J Foren Sci, 30, 1985, pp. 317-337.

Thigpen JT, Vaughn C, and Stuckey WJ, "Phase II Trial of Anguidine in Patients with Sarcomas Unresponsive to Prior Chemotherapy: A Southwest Oncology Group Study," Cancer Treat Rep, 65, 1981, pp. 881-882.

Thompson AR, Inhibition of Thrombin by Sarin, DTIC AD695618, 1969.

Thompson WL, and Wannemacher RW, Jr., "Detection and Quantification of T-2 Mycotoxin with a Simplified Protein Synthesis Inhibition Assay," Appl Environ Microbiol, 1984, pp. 1176-1180.

Thurman JD, Creasia DA, Johnson AJ, "Adrenal Cortical Necrosis Caused by T-2 Mycotoxicosis in Female, but Not Male, Mice," Am J Vet Res, 47, 1986, pp. 1122-1124.

Trusal, LR, "Stability of T-2 Mycotoxin in Aqueous Media," Applied and Environmental Microbiology, November 1985, pp. 1311-1312.

Tutelyan VA, and Kravchenko LV, New Data on Metabolism and Action Mechanism of Mycotoxins, Vestnik Akademii Meditsinskikh Nauk SSSR, trans. from Russian, 1981, pp. 88-89.

U.S. Army Command and General Staff College, Chemical and Biological Weapon Employment, Ft. Leavenworth, KS: U.S. Army Command and General Staff College, 1963.

U.S. Army Medical Research Institute of Chemical Defense, Medical Management of Chemical Casualties Handbook, Aberdeen Proving Ground, Md., 1995.

U.S. Army Medical Research Institute of Infectious Diseases, "Information Sheet: Trichothecene Mycotoxins: Intoxications and Experimental Therapy," Ft. Detrick, Md., 1983.

U.S. Army, Potential Military Chemical/Biological Agents and Compounds, FM 3-9, NAVFAC P-467, AFR 355-7, December 12, 1990.

U.S. Army, XVIII Corps, Dusty Agents Implications for Chemical Warfare Protection (last accessed February 18. 2000, at http://www.gulflink.osd.mil/

Ueno Y, "Toxicological Features of T-2 Toxins and Related Tricothecenes," Fundamental and Applied Toxicology, 4, 1984, pp. S124-S132.

Ueno Y, Developments in Food Science 4, Trichothecenes--Chemical, Biological, and Toxicological Aspects, Tokyo: Kodansha, Ltd., 1983.

Ueno Y, Muto A, and Kobayashi J, Toxicological Properties of T-2 Toxin and Related Trichothecenes, in Heyndrickx (1984), pp. 160-172.

Umeuchi H, Kikuchi C, Matsuoka Y, Sunagane N, Uruno T, and Kubota K, "T-2 Toxin a Mycotoxin from Fusarium Fungi Effect on Learning Ability of Mice" (abstract), Jpn J Pharmacol, 71 (Suppl 1), 1996, pp. 102P.

United Nations Special Commission, Report to the Security Council, New York: United Nations, 1991.

United Nations, Use of Chemical Weapons by Iraqi Regime Report of the Specialists Appointed by the Secretary-General to Investigate Allegations by the Islamic Republic of Iran Concerning the Use of Chemical Weapons, New York, NY: United Nations, 1984.

UNSCOM--see United Nations Special Commission.

USAMRIID--see U.S. Army Medical Research Institute of Infectious Diseases.

Venturini MC, Quiroga MA, Risso MA, Lorenzo CD, Omata Y, Venturini L, and Godoy H, "Mycotoxin T-2 and Aflatoxin B1 as Immunosuppressors in Mice Chronically Infected with Toxoplasma gondii," J Comp Pathol, 115 (3), October 1996, pp. 229-237.

Wang J, Wilson JR, and Fitzpatrick DW, "Central Effects of T-2 Toxin, a Trichothecene Mycotoxin," abstract, Soc Neurosci, 18, 1992, p. 1600.

Wannemacher R, Bunner D, Pace J, Neufeld H, Brenecke L, and Dinterman R, "Dermal Toxicity of T-2 Toxin in Guinea Pigs, Rats, and Cynomolgus Monkeys," Fort Detrick, Md.: U.S. Army Medical Research Institute of Infectious Diseases, DTIC ADA133130, 1983.

Wannemacher RW Jr., and Wiener SL, "Trichothecene Mycotoxins," in Sidell, Takafuji, and Franz (1997), pp. 655-676.

Watson AP, Ambrose KR, Friffin GD, Leffingwell SS, Munro NB, and Waters LC, "Health Effects of Warfare Agent Exposure: Implications for Stockpile Disposal," Environ Prof, 11, 1989, pp. 335-353.

Watson AP, and Griffin GD, "Toxicity of Vesicant Agents Scheduled for Destruction by the Chemical Stockpile Disposal Program," review, Environ Health Perspect, 98, 1992, pp. 259-280.

Watson BW, George B, Tsouras P, and Cyr BL, Military Lessons of the Gulf War, London: Greenhill Books, 1991.

Watson SA, Mirocha CJ, and Hayes AW, "Analysis for Trichothecenes in Samples from Southeast Asia Associated with `Yellow Rain,'" Fund Appl Toxicol, 4, 1984, pp. 700-717.

Yap HY, Murphy WK, DiStefano A, Blumenschein GR, and Bodey GP, "Phase II Study of Anguidine in Advanced Breast Cancer," Cancer Treat Reps, 63, 1979, pp. 789-791.

Yarom R, Sherman Y, More R, Ginsburg I, Borinski R, and Yagen B, "T-2 Toxin Effect in Bacterial Infection and Leukocyte Functions," Toxic Appl Pharmacol, 75, 1984, pp. 60-68.
Get Social With Us

Join 12,500k others who have dealt with toxic mold or are still seeking information to help them fight the battle against toxic mold.  Follow us!

We have questions and answers from the website that take place everyday on our Facebook group.  Join us on our Facebook group by clicking on the Facebook button below.

rss feedemail usour facebook page pintrest youtubeinstagram

Disclaimer

We are not doctors or licensed practitioners.  The advice or suggestions given in the entirety of this website are for informational purposes only.  Please consult your physician before beginning any supplement or regimen. Some statements, treatments or suggestions listed in this website have not been evaluated by the Food and Drug Administration.  This website and/or any of it's contents are not intended to diagnose, treat, cure, or prevent any disease. Read our full disclaimer HERE
Share your Story

Do you have a toxic mold story that you would like to share on SurvivingToxicMold.com?  Send us your story and we will do our best to review it and post it to our "Real Stories" section.  Stories "MUST BE" ready to be published and edited for spelling and grammatical errors.  Please include plenty of photos as well to go along with your story.  Not all stories wil be published.  Stories that are not complete will not be published.
SEND YOUR STORY HERE

 
Read Jennifer's Story


Read (Founder of Surviving Toxic Mold), Jennifer Cannon's full story of mold exposure, loss & hope for healing and a full recovery HERE

 

Contribute to this WEBSITE
Has this website helped you?  Are you looking for a way to give back and help support our mission to spread more awareness about the dangers of toxic mold?
READ MORE & SUPPORT HERE
 

VISIT OUR OTHER WEBSITES

   

 

All rights reserved © 2011-2024 Surviving Toxic Mold

Affiliate Disclosure     |     Sources